Effects of Yeast (1,3)-(1,6)-beta-glucan on immune defence against pathogens of upper respiratory tract infections: a double-blind, randomized, placebo-controlled, monocentric study in healthy subjects - BTS963/16

eiber GmbH0 个研究点目标入组 288 人开始时间: 2016年8月17日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•body mass index (BMI): 18.5 - 32 kg/m²
•- at least 3 common cold episodes within the last 12 months
•- subject is able and willing to sign the Informed Consent Form prior to screening evaluations
•- not anticipating any planned changes in lifestyle regarding activity, nutrition, sleep habits and / or expected stress level
•- subject is in good physical and mental health

•- intake of medications or food supplements with influence on the immune system or anti-inflammatory products
•- chronic respiratory illness (e.g. chronic cough, chronic rhinitis)
•- allergies that may influence the upper respiratory tract (e.g. allergic rhinitis, allergic asthma)
•- gastorintestinal diseases / conditions (e.g. colitis ulcerosa, Crohn's IBS, IBD, peptic ulcers, celiac disease)
•- Influenza vaccination within the previous three weeks prior to or during the trial
•- heavy smoker > 15 cigarettes / day
•- known drug, alcohol or medication abuses
•- known pregnancy, breast feeding or intention to become pregnant during the study
•- Blood donation within 4 weeks prior to trial start or during trial

发起方

eiber GmbH